- Craneware expects full year revenues to be in the range of $44.5m to $45m (FY14: $42.6m) and adjusted EBITDA in the range of $14.0m to $14.5m (FY14: $13.1m).

Craneware - the market leader in automated revenue integrity solutions for the US healthcare market - said the total value of contracts signed for the year was $72.5m, building on the previous year's record sales performance.

As the group's revenue recognition policy retains focus on long term sustainable growth and mitigates against year on year fluctuations in the total value of contracts signed, the vast majority of the revenue from these sales has not been recognised in the year to 30 June, and will instead benefit future years.

Chief executive Keith Neilson said: "We are delighted with the continued level of strong sales throughout the period that underpin the group's financial and operational performance. We believe this continues to demonstrate our solutions' importance in supporting US hospitals as they transition towards value based healthcare.

"Having now defined the 'value cycle' for US Healthcare providers, Craneware's leading position in providing solutions to discover, convert and optimise value for them along with the Group's ongoing financial performance, gives management confidence in its ability to deliver continued and increasing stakeholder value." The company will announce its full year results on 8 September.

At 8:14am: [LON:CRW] Craneware PLC share price was 0p at 655p

Story provided by